On Friday, CNBC had on the CEO of Compass Pathways (CMPS), the only publicly traded company currently conducting clinical trials of psilocybin from mushrooms. Following the segment, CMPS rallied by $4.19 or 12.25% to close at $38.39 per share where it now has a market cap of $1.336 billion.
One month ago on Sunday, September 27th after CMPS had finished the previous week at a record high closing price of $43.17 per share, NIA sent out an alert announcing Numinus Wellness (TSXV: NUMI) at $0.285 per share as its #1 favorite psychedelic stock and one of its Top 5 favorite overall stock suggestions. On Friday, NUMI gained by $0.045 or 11.84% to close at $0.425 per share, which is a new high since NIA's initial suggestion. NUMI is already up by 49.12% from NIA's suggestion price vs. CMPS dipping by 11.07% during this same time period.
We are watching Revive Therapeutics (CSE: RVV) very closely. RVV could soon become the only publicly traded company to conduct clinical trials of psilocybin for the treatment of a disorder that currently has no FDA approved pharmacological treatments. Although the FDA has approved three drugs for the treatment of opioid addiction: buprenorphine, methadone, and extended-release naltrexone, there are currently no medications approved by the FDA to treat methamphetamine use disorder. RVV has entered into a Clinical Trial Agreement (CTA) with the Board of Regents of the University of Wisconsin System (UWS) to conduct a clinical study entitled, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.”
One week ago on the afternoon of Monday, October 19th, NIA said that it loved Fiore Gold (TSVX: F) at $1.56 per share and predicted, "Within the next few trading days look for Fiore to announce record annual gold production for its fiscal year 2020, which ended on September 30, 2020." The very next day, Fiore announced that it produced a record 46,031 oz of gold in fiscal year 2020 including 4Q production of 12,432 oz, which is equal to 49,728 oz on an annualized basis. Fiore's cash position increased by $5.9 million or 34.1% during 4Q 2020 to a record US$23.2 million, which means it will probably report strong free cash flow and net income for the 4Q when they release their full year 2020 financial results. Fiore closed Friday at $1.63 per share up by $0.07 or 4.49% from our update one week ago and we believe it will have little/no resistance when it returns to $1.70 per share, which will be its next key breakout point.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has been compensated by NUMI USD$30,000 cash for a six-month marketing contract. NIA has been compensated by RVV USD$30,000 cash and expects to receive 200,000 restricted common shares of RVV stock for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
